

From: [REDACTED]@efpia.eu>
Sent: Wednesday, May 3, 2023 3:44 PM
To: ECHA EO <executive-director@echa.europa.eu>
Cc: [REDACTED]@efpia.eu>; [REDACTED]@cefic.be>;
[REDACTED]@nl.aspenpharma.com; [REDACTED]
[REDACTED]@merckgroup.com>
Subject: EFPIA & EFCG Outreach on PFAS Restriction

CAUTION: This email originated from outside ECHA. Do not click links or open attachments unless you know the content is safe.

Check the email address of the sender. It is possible that the name of the sender is known to you (e.g. a colleague), but the actual sender is someone else.

Dear Ms McGuinness

With this I am writing to you in my capacity as a chemical expert within EFPIA (European Federation of Pharmaceutical Industries Association), an accredited stakeholder observer at ECHA.

On Tuesday 25 April EFPIA and EFCG (European Fine Chemicals Group) had good engagement with representatives from the competent authorities of the Netherlands, Norway, and Sweden on the PFAS restriction consultation process. However, during our discussions, it became apparent that there are some questions that are best answered by ECHA personnel.

PFAS type materials are used throughout the supply chain of medicinal products and in the plant and equipment within pharmaceutical manufacturing facilities. To help the ECHA Committees, we would like clarification on the environmental and socio-economic impact assessment that our sector needs to provide during the public consultation.

Given the tight time frame that is involved, we believe it would be better if our discussions occur in person and will travel to Helsinki, or wherever is convenient. To that extent if you could assist with arranging a meeting with the relevant ECHA personnel it would be much appreciated.

It is recognised that this is a very busy time for you, and we greatly appreciate any consideration given to this request.

Kind regards,

--

[REDACTED]
European Federation of Pharmaceutical Industries and Associations
Leopold Plaza Building
Rue du Trône 108
B-1050 Brussels (Belgium)
Tel: +353 (0) 86 152 [REDACTED] (mobile)
Email: [REDACTED]@efpia.eu
www.efpia.eu